Promising results for Accusite injectable gel
This article was originally published in Clinica
Executive Summary
Interim clinical results have shown 100% success for Matrix Pharmaceutical's (US) Accusite injectable gel in treating squamous cell carcinoma skin cancers. The gel was injected in 15 patients with lesions once weekly for six weeks in a Phase II study, and after a further 16 weeks all patients were cured. The data are part of a 25-patient study which will be completed this year.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.